BioSpace News Archive

SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer.

Societal CDMO, Inc. announced that it has signed an amendment to its license and supply agreement with Lannett Company for the marketing of Verapamil PM and Verelan SR products.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced it has reached a key milestone on the path to commercialization of Rhenium-186 NanoLiposome (186RNL) as the Company completed the technology transfer and initiation of cGMP manufacturing of the 186RNL drug intermediate with Piramal Pharma Solutions (PPS).

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at 7th JCA-AACR Special Joint Conference (July 8-10, 2022) is now available at https://www.oncotelic.com/wp-content/uploads/2022/07/JCA-2022.pptx.pdf and https://www.youtube.com/watch?v=D9h7ExvUUVs .

Nanoscope Therapeutics Inc. announced that clinical development of its Multi-Characteristic Opsin gene therapy platform will be featured in two presentations at the 2022 Annual Scientific Meeting of the American Society of Retina Specialists, taking place July 13 – 16, in New York City.

ACELYRIN, INC. announced the appointment of Gil M. Labrucherie as Chief Financial Officer effective July 18.

Pyxis Oncology, Inc. reported on July 1, 2022 that Pyxis Oncology’s Board of Directors granted restricted stock units with respect to an aggregate of 61,360 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 76,701 shares of Pyxis Oncology’s common stock to four newly hired employees.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its online training module for physical therapists seeking to treat gait deficit in adults with mild to moderate symptoms of multiple sclerosis (“MS”).

ImmuneID today announced the appointment of Pam Stetkiewicz, Ph.D. to its Board of Directors as a representative of ARCH Venture Partners.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Bones require stabilization for healing.